NAMSA
Private Company
Total funding raised: $150M
Overview
NAMSA is a long-established and specialized CRO focused exclusively on the medical device and diagnostics sectors, offering an integrated suite of services for product development and regulatory approval. Its business model is built on providing essential outsourced expertise in biocompatibility testing, clinical research, quality assurance, and regulatory strategy, primarily to device manufacturers. As a private company, it operates globally, leveraging deep regulatory knowledge to accelerate client time-to-market. Its position is strengthened by the consistently high demand for regulatory and testing services driven by stringent global medical device regulations.
Technology Platform
Integrated service platform for medical device development, including biological safety testing (ISO 10993), chemical characterization, microbiology, regulatory strategy, clinical trial management, and quality systems consulting.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
NAMSA competes with other specialized medical device CROs like Eurofins Medical Device Testing, WuXi AppTec's medical device unit, and NSF International, as well as the device-focused divisions of larger, broad-based CROs (e.g., ICON, Labcorp). Its key differentiator is its deep, exclusive focus on the full medical device and IVD lifecycle, offering integrated testing and regulatory strategy under one roof.